查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595561

Pregabalin市场：按剂型、药物类别、应用、最终用户、通路 - 全球预测 2025-2030

Pregabalin Market by Dosage Forms (Extended Release, Oral Capsule, Oral Solution), Drug Class (Anticonvulsants, Fibromyalgia Agents), Application, End-Users, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年Pregabalin市场价值为11.2亿美元，预计到2024年将达到12亿美元，复合年增长率为7.74%，预计到2030年将达到18.9亿美元。

Pregabalin是一种主要用于治疗神经痛、癫痫和整体焦虑症的药物，由于其广泛的治疗用途，在全球医药市场中占据重要份额。对Pregabalin的需求源于其在治疗神经病变疼痛、纤维肌痛和癫痫相关疾病方面的有效性，从而在医疗保健领域产生了强劲的需求。最终用途主要包括医院、诊所和家庭护理机构，因为这些疾病的发生率在全球范围内不断增加。加强Pregabalin市场的主要影响因素包括慢性疼痛疾病盛行率的上升、易受神经损伤的老年人口的增加以及对神经病变疼痛的认识和诊断的提高。此外，正在进行的研究和开发旨在扩大治疗适应症并提高药物疗效，从而提供新的成长机会。最近的潜在机会包括开出副作用较少的替代药物以及修改当前剂量以提高安全性和有效性。为了充分利用这些机会，製造商可能会专注于创新药物输送系统和学名药，以开拓开拓的市场。然而，这些成长前景受到诸如严格的法律规范、滥用导致依赖性问题的可能性以及影响患者获取的高药物成本等挑战的限制。替代疗法和专利到期带来的激烈竞争也构成了市场威胁。然而，潜在的创新和研究领域正在出现，包括开发基于奈米技术的製剂以及考虑与其他药物组合以增强治疗效果。此外，市场相关人员可能会追求基于价值的定价策略，以在不影响盈利的情况下提高可及性。该市场竞争激烈且有望成长，需要策略联盟和持续的研发投资，以解决现有限制并有效开拓新的市场前景。

主要市场统计
基准年[2023] 11.2亿美元
预测年份 [2024] 12亿美元
预测年份 [2030] 18.9亿美元
复合年增长率（%） 7.74%

市场动态：揭示快速发展的Pregabalin市场的关键市场洞察

供需的动态交互作用正在改变Pregabalin市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 癫痫和焦虑症病例增加
    • 政府积极努力提高对焦虑症的认识
    • 患有神经病变疼痛的老年人口不断增加
  • 市场限制因素
    • 替代品的存在与缺乏意识
  • 市场机会
    • 学名药核准增加
    • Pregabalin的进展与产品增强
  • 市场挑战
    • 不良健康影响和产品召回

波特的五力：驾驭Pregabalin市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解Pregabalin市场的外部影响

外部宏观环境因素在塑造Pregabalin市场的业绩动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解Pregabalin市场的竞争状况

对Pregabalin市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵Pregabalin市场供应商绩效评估

FPNV定位矩阵是评估Pregabalin市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製Pregabalin市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，Pregabalin市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 癫痫和焦虑症增加
      • 政府为提高对不安全问题的认识而采取的有利倡议
      • 患有神经病变疼痛的老年人口不断增加
    • 抑制因素
      • 替代品的存在与缺乏意识
    • 机会
      • 学名药核准增加
      • Pregabalin的进展与产品增强
    • 任务
      • 不良健康影响和产品召回
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章Pregabalin市场按剂型

  • 延长释放
  • 口服胶囊
  • 口服液
  • 口服锭剂

第七章依药物类别分類的Pregabalin市场

  • 抗惊厥药
  • 纤维肌痛治疗药物

第八章Pregabalin市场：依应用分类

  • 焦虑症
  • 癫痫
  • 神经病变疼痛

第 9 章Pregabalin市场：依最终用户分类

  • 居家护理
  • 医院
  • 调查机构
  • 专科诊所

第10章Pregabalin市场：依通路分类

  • 医院药房
  • 网路药房
  • 零售药房

第十一章 美洲Pregabalin市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章 亚太地区Pregabalin市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章 欧洲、中东和非洲Pregabalin市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Almelo Private Limited
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma Limited
  • BAL Pharma Ltd.
  • Cipla Limited
  • Dongbang FTL
  • Genesis Biotec Inc.
  • Hikal Ltd.
  • Lupin Limited
  • Medley Pharmaceuticals Limited
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Limited
Product Code: MRR-957C47F916B3

The Pregabalin Market was valued at USD 1.12 billion in 2023, expected to reach USD 1.20 billion in 2024, and is projected to grow at a CAGR of 7.74%, to USD 1.89 billion by 2030.

Pregabalin, a medication primarily used to treat nerve pain, seizures, and generalized anxiety disorder, represents a significant segment of the global pharmaceutical market due to its broad therapeutic applications. The necessity for pregabalin arises from its efficacy in managing conditions associated with neuropathic pain, fibromyalgia, and epilepsy, creating a robust demand in the healthcare sector. End-use scope primarily includes hospitals, clinics, and homecare settings, tapping into the increasing incidence of such conditions worldwide. Key influencing factors bolstering the pregabalin market include the rising prevalence of chronic pain disorders, expanding geriatric population susceptible to nerve damage, and increasing awareness and diagnosis of neuropathic pain. Moreover, ongoing research and development are aimed at expanding therapeutic indications and improving drug efficacy, presenting new growth opportunities. Recent potential opportunities include formulating pregabalin alternatives with fewer side effects and modifying current dosages to enhance safety and efficacy. To maximize these opportunities, manufacturers could focus on innovative drug delivery systems and generic versions to tap into untapped markets. However, these growth prospects are tempered by challenges such as stringent regulatory frameworks, potential misuse leading to dependency concerns, and the high cost of medication, impacting patient access. Fierce competition from alternative therapies and the expiration of patents further pose market threats. Nonetheless, areas for potential innovation and research are emerging in developing nanotechnology-based formulations and exploring combinations with other drugs to enhance therapeutic outcomes. Additionally, market players could pursue value-based pricing strategies to enhance accessibility without compromising profitability. The nature of the pregabalin market is highly competitive yet poised for growth, with a need for strategic collaborations and continued investment in R&D to address existing limitations and capitalize on new market prospects efficiently.

KEY MARKET STATISTICS
Base Year [2023] USD 1.12 billion
Estimated Year [2024] USD 1.20 billion
Forecast Year [2030] USD 1.89 billion
CAGR (%) 7.74%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pregabalin Market

The Pregabalin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing cases of epilepsy and anxiety disorders
    • Favorable government initiatives for raising awareness for anxiety issues
    • Rising geriartic population with neuropathic pain
  • Market Restraints
    • Presence of substitutes and lack of awareness
  • Market Opportunities
    • Rising approvals of generic versions of the medicine
    • Advancements and product enhancements for pregabalin
  • Market Challenges
    • Adverse effects on health and product recalls

Porter's Five Forces: A Strategic Tool for Navigating the Pregabalin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pregabalin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pregabalin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pregabalin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pregabalin Market

A detailed market share analysis in the Pregabalin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pregabalin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pregabalin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pregabalin Market

A strategic analysis of the Pregabalin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pregabalin Market, highlighting leading vendors and their innovative profiles. These include Almelo Private Limited, Amneal Pharmaceuticals LLC, Aurobindo Pharma Limited, BAL Pharma Ltd., Cipla Limited, Dongbang FTL, Genesis Biotec Inc., Hikal Ltd., Lupin Limited, Medley Pharmaceuticals Limited, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Pregabalin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Dosage Forms, market is studied across Extended Release, Oral Capsule, Oral Solution, and Oral Tablet.
  • Based on Drug Class, market is studied across Anticonvulsants and Fibromyalgia Agents.
  • Based on Application, market is studied across Anxiety Disorder, Epilepsy, and Neuropathic Pain.
  • Based on End-Users, market is studied across Homecare, Hospitals, Research institute, and Specialty Clinics.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing cases of epilepsy and anxiety disorders
      • 5.1.1.2. Favorable government initiatives for raising awareness for anxiety issues
      • 5.1.1.3. Rising geriartic population with neuropathic pain
    • 5.1.2. Restraints
      • 5.1.2.1. Presence of substitutes and lack of awareness
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising approvals of generic versions of the medicine
      • 5.1.3.2. Advancements and product enhancements for pregabalin
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects on health and product recalls
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pregabalin Market, by Dosage Forms

  • 6.1. Introduction
  • 6.2. Extended Release
  • 6.3. Oral Capsule
  • 6.4. Oral Solution
  • 6.5. Oral Tablet

7. Pregabalin Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Anticonvulsants
  • 7.3. Fibromyalgia Agents

8. Pregabalin Market, by Application

  • 8.1. Introduction
  • 8.2. Anxiety Disorder
  • 8.3. Epilepsy
  • 8.4. Neuropathic Pain

9. Pregabalin Market, by End-Users

  • 9.1. Introduction
  • 9.2. Homecare
  • 9.3. Hospitals
  • 9.4. Research institute
  • 9.5. Specialty Clinics

10. Pregabalin Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacy
  • 10.3. Online Pharmacy
  • 10.4. Retail Pharmacy

11. Americas Pregabalin Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Pregabalin Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Pregabalin Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Almelo Private Limited
  • 2. Amneal Pharmaceuticals LLC
  • 3. Aurobindo Pharma Limited
  • 4. BAL Pharma Ltd.
  • 5. Cipla Limited
  • 6. Dongbang FTL
  • 7. Genesis Biotec Inc.
  • 8. Hikal Ltd.
  • 9. Lupin Limited
  • 10. Medley Pharmaceuticals Limited
  • 11. Novartis AG
  • 12. Pfizer Inc.
  • 13. Teva Pharmaceutical Industries Ltd.
  • 14. Torrent Pharmaceuticals Ltd.
  • 15. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. PREGABALIN MARKET RESEARCH PROCESS
  • FIGURE 2. PREGABALIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PREGABALIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PREGABALIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PREGABALIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PREGABALIN MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PREGABALIN MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PREGABALIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PREGABALIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PREGABALIN MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PREGABALIN MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS PREGABALIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS PREGABALIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES PREGABALIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES PREGABALIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PREGABALIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PREGABALIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. PREGABALIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. PREGABALIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PREGABALIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PREGABALIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PREGABALIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PREGABALIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PREGABALIN MARKET DYNAMICS
  • TABLE 7. GLOBAL PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PREGABALIN MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PREGABALIN MARKET SIZE, BY ORAL CAPSULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PREGABALIN MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PREGABALIN MARKET SIZE, BY ORAL TABLET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PREGABALIN MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PREGABALIN MARKET SIZE, BY FIBROMYALGIA AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PREGABALIN MARKET SIZE, BY ANXIETY DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PREGABALIN MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PREGABALIN MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PREGABALIN MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PREGABALIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PREGABALIN MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PREGABALIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PREGABALIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PREGABALIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PREGABALIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS PREGABALIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES PREGABALIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA PREGABALIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. PREGABALIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 238. PREGABALIN MARKET, FPNV POSITIONING MATRIX, 2023